Rigel Pharmaceuticals RIGL Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rigel Pharmaceuticals's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rigel Pharmaceuticals's retained earnings?
- Rigel Pharmaceuticals (RIGL) reported retained earnings of -$1.01B in Q1 2026.
- How has Rigel Pharmaceuticals's retained earnings changed year-over-year?
- Rigel Pharmaceuticals's retained earnings increased by 26.4% year-over-year, from -$1.38B to -$1.01B.
- What is the long-term trend for Rigel Pharmaceuticals's retained earnings?
- Over 5 years (2020 to 2025), Rigel Pharmaceuticals's retained earnings has grown at a -4.8% compound annual growth rate (CAGR), from -$1.31B to -$1.02B.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.